Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SARS-CoV-2 Omicron (BA.5) Challenge Study
NCT06492564Phase 1Completed
- Sponsor
- hVIVO
- Start
- Dec 2024
- Primary completion
- Oct 2025
- Modality
- Biologic
- Countries
- 1
01
Overview
Phase 1, open-label trial of SARS-CoV-2 omicron virus in Coronavirus Disease 2019 (COVID-19) (3 arms), sponsored by hVIVO. Primary endpoints: Occurrence of Adverse Events related to the viral challenge at Day 28, Occurrence of Serious Adverse Events and Medically Attended Adverse Events at Day 180 and 1 more. Started Dec 2024; status: completed.
02
Drugs
SARS-CoV-2 omicron virus
03
Conditions
Coronavirus Disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT06492564.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06492564.